Combining Minimally Invasive Bariatric Surgery With Semaglutide Increases Weight Loss

Pairing semaglutide, a drug used to deal with diabetes, with a minimally invasive endoscopic sleeve gastroplasty (ESG) can present vital weight reduction advantages for sufferers who aren’t candidates for invasive weight reduction surgical procedure, in accordance with a examine offered at Digestive Disease Week 2021.For the double-blind examine, the researchers randomized 61 sufferers present process ESG into 2 teams: 1 receiving semaglutide—an injectable glucagon-like peptide-1 receptor that has been discovered to stimulate weight reduction—1 month after the process, and the opposite receiving a placebo administered by look-alike injector pens. Participants had been monitored every month for physique weight and physique composition, with blood panels taken each 3 months.According to the authors of the examine, sufferers receiving semaglutide misplaced 26.7% of their whole physique weight on common, in comparison with 19.6% within the management group. The semaglutide group misplaced 86.3% of their extra weight (the quantity of weight the individuals wanted to lose to achieve regular BMI) in comparison with 60.4% for the management group. Additionally, physique fats by weight decreased by 12.7% within the semaglutide group versus 9% within the management group, and glycated hemoglobin ranges fell 0.95 for the semaglutide group and 0.61 for the controls.“As the worldwide weight problems charge continues to climb, so do the variety of folks looking for bariatric surgical procedure to deal with their situation,” stated Anna Carolina Hoff, MD, lead researcher on the examine and founder and scientific director of Angioskope Brazil, São José dos Campos, in a press launch. “Surgical procedures are among the most profitable methods to assist sufferers shed extra pounds, however they’ll finally include problems. Our examine reveals that sufferers could not should bear invasive surgical procedure to get comparable outcomes.”More invasive surgical procedures, reminiscent of laparoscopic sleeve gastrectomy, include elevated prices and a better threat for problems, reminiscent of gastroesophageal reflux illness. These procedures are usually restricted to sufferers with a BMI of at the very least 35 with comorbidities, or a BMI above 40.ESG might be carried out at an earlier stage of illness and at a decrease BMI, permitting extra sufferers to get the therapy they want earlier than their illness progresses. Providing earlier therapy to sufferers with weight problems can scale back the danger of mortality and comorbidities, in addition to decrease prices related to therapy.“ESG has been accessible to sufferers for years, but it surely has not all the time been as profitable as surgical choices in serving to sufferers shed extra pounds,” Hoff stated within the launch. “We now have a minimally invasive process that may be simply as profitable when mixed with semaglutide and might be made accessible to much more folks trying to lose a big quantity of weight.”ESG is carried out by guiding a tool by the affected person’s throat into the abdomen, the place an endoscopist makes use of sutures to lower the dimensions of the abdomen. This assists in weight reduction by limiting the quantity {that a} affected person can eat. Patients are candidates for ESG if they’ve a BMI at or above 30, and weight loss program and train haven’t helped them shed extra pounds, or if they aren’t a candidate for surgical procedure, or don’t want to pursue surgical procedure.Long-term sturdiness of the therapy nonetheless has but to be decided, in accordance with the researchers.REFERENCEPairing bariatric process with diabetes drug will increase weight reduction [news release]. EurekAlert; May 14, 2021. Accessed May 17, 2021.

Recommended For You